Abbvie is a general drug manufacturer company located in Illinois, United States, which is part of the Healthcare sector, and is traded under the ticker ABBV on the NYSE exchange.
Abbvie stock last closed at $224.95, down 0.21% from the previous day, and has increased 18.71% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.11 percentage points. Abbvie stock is currently +23.78% from its 52-week low of $181.73, and -8.11% from its 52-week high of $244.81.
As of Jun 10, 2026, there are 1.77B shares of ABBV outstanding. The market value of ABBV is $397.44B. In the last 24 hours, 4.13M ABBV shares were traded.
You need a brokerage account in order to access the NYSE market and buy ABBV shares.
In our opinion, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, it's time to fill out some personal details so you are able to invest in ABBV stock today.
Now that you have opened your account on a good stock buying app, you need to deposit funds:
Check out the walkthrough below if you need help depositing money into your brokerage account.
After you have figured out the best place to buy Abbvie stock, it's important to research their stock before you buy, so you can comprehend the risk as well as the opportunity.
WallStreetZen was created to help part-time investors perform better fundamental analysis quickly.
You can view all of the due diligence checks on ABBV's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge ABBV's true value.
Using relative valuations metrics:
You can access additional valuation analysis on ABBV's stock here.
Out of 11 sell side analysts who give ratings on ABBV, the consensus analyst rating on Abbvie is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Carter Gould, a top 13% analyst from Cantor Fitzgerald reiterates ABBV with a strong buy rating and maintains their ABBV price target from $240.00 to $240.00, on Apr 30, 2026.
Trung Huynh, a top 10% analyst from RBC Capital initiates coverage on ABBV with a buy rating and announces their ABBV price target of $260.00, on Feb 25, 2026.
RBC Capital's Trung Huynh initiated their coverage on Abbvie (NYSE: ABBV) with a Buy rating and a $260 price target.
Initiating their coverage on AbbVie, Huynh backgrounded that the stock has underperformed because of concerns its "beat-and-raise" story is winding down, and competition is threatening its immunology growth.
The analyst said they disagree and expect continued outperformance because "AbbVie remains early in indication expansion."
Emily Field, a top 44% analyst from Barclays initiates coverage on ABBV with a strong buy rating and announces their ABBV price target of $275.00, on Feb 20, 2026.
Ilya Zubkov, a bottom 6% analyst from Freedom Broker maintains ABBV with a strong buy rating and raises their ABBV price target from $245.00 to $260.00, on Feb 17, 2026.
Michael Yee, a top 20% analyst from UBS maintains ABBV with a hold rating and lowers their ABBV price target from $240.00 to $230.00, on Feb 5, 2026.
You can dive deeper into what analysts are forecasting on the Abbvie stock forecast page.
Last year, ABBV earnings were $3.64B. Over the last 5 year, ABBV's earnings have grown by -6.16% per year. This was slower than the Drug Manufacturers - General industry average of 16.64%.
Last year, ABBV revenue was $62.82B. Over the past five year, ABBV's revenue has grown by 4.59% per year. This was slower than the Drug Manufacturers - General industry average of 10.87%.
Dig into ABBV's earnings and revenue performance here.
Over the last 12 months, executives and large shareholders at ABBV have sold more shares than they have bought.
David Ryan Purdue, SVP Controller of ABBV, was the latest ABBV insider to sell. They sold $1,221,518.80 worth of ABBV stock on Mar 4, 2026.
Learn more about who owns ABBV shares here.
Abbvie pays a dividend of 3%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.76%. If you owned $1,000 worth of ABBV stock, you would have received $29.96 in the past 12 months.
Abbvie dividend payments have consistently grown over the past decade and have remained stable.
Get more info about Abbvie dividend yield and history here.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
There are two main options:
Press the Open Trade button and your broker will place the order.
If you require additional assistance investing in stocks on eToro, click the how to video below:
Now that you own some shares in ABBV, you'll want to keep up with your investment.
Put ABBV on a watchlist to see the latest developments about your ABBV stock.
To reiterate, here are the 6 steps to buy stock in Abbvie:
If you require a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to monitor your investment in Abbvie, create a watchlist today.